IGMS Logo

IGM Biosciences, Inc. (IGMS) 

NASDAQ
Market Cap
$616.64M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
64 of 966
Rank in Industry
48 of 554

Largest Insider Buys in Sector

IGMS Stock Price History Chart

IGMS Stock Performance

About IGM Biosciences, Inc.

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Insider Activity of IGM Biosciences, Inc.

Over the last 12 months, insiders at IGM Biosciences, Inc. have bought $6.86M and sold $881,039 worth of IGM Biosciences, Inc. stock.

On average, over the past 5 years, insiders at IGM Biosciences, Inc. have bought $45.43M and sold $1.96M worth of stock each year.

Highest buying activity among insiders over the last 12 months: BAKER BROS. ADVISORS LP () — $116.57M.

The last purchase of 97,473 shares for transaction amount of $937,632 was made by BAKER BROS. ADVISORS LP () on 2024‑03‑28.

List of Insider Buy and Sell Transactions, IGM Biosciences, Inc.

2024-09-13SaleCEO AND PRESIDENT
3,946
0.0062%
$11.54$45,532+17.89%
2024-09-13SaleCHIEF SCIENTIFIC OFFICER
1,487
0.0023%
$11.54$17,158+17.89%
2024-09-13SaleHead, Research & Autoimmunity
1,487
0.0023%
$11.54$17,158+17.89%
2024-09-13SaleCHIEF MEDICAL OFFICER
1,487
0.0023%
$11.54$17,158+17.89%
2024-09-13SaleCHIEF FINANCIAL OFFICER
1,487
0.0023%
$11.54$17,158+17.89%
2024-09-13SaleCHIEF BUSINESS OFFICER
925
0.0015%
$11.54$10,673+17.89%
2024-09-13SalePRINCIPAL ACCOUNTING OFFICER
469
0.0007%
$11.54$5,412+17.89%
2024-07-25Saledirector
15,132
0.0297%
$14.00$211,848-7.60%
2024-06-14SaleCEO AND PRESIDENT
4,164
0.0067%
$7.58$31,544+48.35%
2024-06-14SaleCHIEF SCIENTIFIC OFFICER
1,106
0.0018%
$7.58$8,378+48.35%
2024-06-14SaleCHIEF MEDICAL OFFICER
1,570
0.0025%
$7.58$11,893+48.35%
2024-06-14SaleCHIEF FINANCIAL OFFICER
1,570
0.0025%
$7.58$11,893+48.35%
2024-06-14SaleHead, Research & Autoimmunity
1,570
0.0025%
$7.58$11,893+48.35%
2024-06-14SaleCHIEF BUSINESS OFFICER
977
0.0016%
$7.58$7,401+48.35%
2024-06-14SalePRINCIPAL ACCOUNTING OFFICER
495
0.0008%
$7.58$3,750+48.35%
2024-03-28Purchase
97,473
0.1653%
$9.62$937,632+0.83%
2024-03-27Purchase
27,844
0.0472%
$9.24$257,170+4.42%
2024-03-26Purchase
270,000
0.4372%
$8.26$2.23M+11.58%
2024-03-14SaleCEO AND PRESIDENT
4,182
0.0073%
$10.17$42,533-3.77%
2024-03-14SaleCHIEF SCIENTIFIC OFFICER
1,844
0.0032%
$10.17$18,754-3.77%

Insider Historical Profitability

29.14%
BAKER BROS. ADVISORS LP
3753480
6.3122%
$10.3770
Schwarzer FredCEO AND PRESIDENT
250124
0.4206%
$10.37010
Keyt BruceCHIEF SCIENTIFIC OFFICER
242948
0.4086%
$10.37031
Harler Mary BethHead, Research & Autoimmunity
163740
0.2754%
$10.3702
Takimoto Chris HCHIEF MEDICAL OFFICER
154331
0.2595%
$10.37010
Tahir MisbahCHIEF FINANCIAL OFFICER
122694
0.2063%
$10.37011
Decker Lisa LynnCHIEF BUSINESS OFFICER
79104
0.133%
$10.37011
Weber StevenPRINCIPAL ACCOUNTING OFFICER
25543
0.043%
$10.3704
Hambleton Juliedirector
2000
0.0034%
$10.3713+104.4%
Topsoe Holding A/S10 percent owner
5044295
8.4829%
$10.3740+25.62%
Green Jeremy
4500225
7.568%
$10.3710<0.0001%
Redmile Group, LLCdirector
2974186
5.0016%
$10.3771+49.57%
Baker Brothers Life Sciences LP
421532
0.7089%
$10.3710<0.0001%
BEHRENS M KATHLEENdirector
330700
0.5561%
$10.3770+23.89%
Chen Daniel ShinYuChief Medical Officer
116518
0.1959%
$10.37015
Topsoe Jakob Haldor
81644
0.1373%
$10.37100+42.2%
Gauthier GeorgeChief Commercial Officer
39642
0.0667%
$10.3709
LOBERG MICHAEL Ddirector
35305
0.0594%
$10.3750+0.84%
Topsoe Christina Teng
9800
0.0165%
$10.3760+19.55%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Baker Bros Advisors LP$39.45M6.934.09M+10.76%+$3.83M0.28
T. Rowe Price$37.52M6.593.89M+19.26%+$6.06M0.01
Artal Group S A$29.73M5.223.08M-0.65%-$193,000.000.13
Redmile Group$29.65M5.213.07M+3.4%+$974,032.410.3
Fidelity Investments$12.71M2.231.32M-22.44%-$3.68M<0.01
Goldman Sachs$12.34M2.171.28M+22.88%+$2.3M<0.01
RA Capital Management, L.P.$9.05M1.59937,5000%+$00.01
The Vanguard Group$8.24M1.45853,658-4.85%-$419,688.16<0.0001
BlackRock$7.31M1.28757,963-0.59%-$43,492.56<0.0001
Millennium Management LLC$6.71M1.18695,061+181.18%+$4.32M<0.01
Geode Capital Management$3.24M0.57336,005+2.86%+$90,228.58<0.0001
State Street$3.08M0.54319,269+3.84%+$113,879.66<0.0001
RHENMAN & PARTNERS ASSET MANAGEMENT AB$1.88M0.33195,000-2.5%-$48,250.000.18
Td Asset Management Inc$1.54M0.27159,122+90.67%+$730,215.36<0.01
Samsara Biocapital Llc$1.49M0.26154,6640%+$00.23
Northern Trust$1.32M0.23137,236+0.32%+$4,246.00<0.0001
Charles Schwab$1.17M0.21121,118+0.25%+$2,904.65<0.0001
Morgan Stanley$975,568.000.17101,095+6.37%+$58,421.18<0.0001
D. E. Shaw & Co.$899,023.000.1693,163+97.19%+$443,108.72<0.01
Jacobs Levy Equity Management$758,297.000.1378,580New+$758,297.00<0.01
Woodline Partners LP$723,750.000.1375,0000%+$00.01
Marshall Wace$682,988.000.1270,776New+$682,988.00<0.01
The Manufacturers Life Insurance Company$680,335.000.1270,501+44.05%+$208,044.46<0.01
Pennant Capital Management Llc$626,285.000.1164,9000%+$00.1
Bruce Co Inc$627,250.000.1165,0000%+$00.26
Wellington Management Company$551,884.000.157,190New+$551,884.00<0.0001
BNY Mellon$478,186.000.0849,553-4.7%-$23,584.58<0.0001
Renaissance Technologies$464,000.000.0848,100+31.42%+$110,935.55<0.01
Eagle Bay Advisors Llc$430,728.000.0844,6350%+$00.28
Nuveen$393,228.000.0740,749-18.21%-$87,564.13<0.0001
Dimensional Fund Advisors$380,722.000.0739,4530%+$0<0.0001
AllianceBernstein$311,695.000.0632,3000%+$0<0.0001
Jane Street Capital$300,308.000.0531,120-12.67%-$43,569.75<0.0001
Exchange Traded Concepts, LLC$269,573.000.0527,935+46.66%+$85,759.630.01
Susquehanna Fundamental Investments Llc$267,604.000.0527,731New+$267,604.000.01
Trexquant Investment LP$233,308.000.0424,177New+$233,308.00<0.01
Panagora$225,028.000.0423,319-22.97%-$67,106.00<0.01
Bank of America$214,924.000.0422,272-9.95%-$23,738.91<0.0001
ExodusPoint Capital Management, LP$196,000.000.0320,323New+$196,000.00<0.01
Walleye Capital$193,483.000.0320,050New+$193,483.00<0.01
RhumbLine Advisers$193,870.000.0320,091+4.62%+$8,559.19<0.0001
Barclays$184,000.000.0319,054-22.45%-$53,266.72<0.0001
Gsa Capital Partners Llp$178,000.000.0318,398New+$178,000.000.01
American Century Investments$165,083.000.0317,107New+$165,083.00<0.0001
Two Sigma$167,283.000.0317,335New+$167,283.00<0.0001
Virtus ETF Advisers LLC$128,654.000.0213,332-6.4%-$8,791.160.04
UBS$128,644.000.0213,331+0.99%+$1,264.15<0.0001
Citadel Advisors LLC$127,023.000.0213,163-93.78%-$1.91M<0.0001
Xtx Topco Ltd$115,231.000.0211,941New+$115,231.00<0.01
Pale Fire Capital Se$111,950.000.0211,6010%+$0<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.